Literature DB >> 3566236

Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters.

G W Elmer, L V McFarland.   

Abstract

Saccharomyces boulardii prevented the development of high counts of Clostridium difficile, high titers of toxin B, and positive latex agglutination tests after cessation of vancomycin treatment for hamsters. The protocol used was designed to stimulate relapse of human C. difficile-associated colitis. S. boulardii was protective in this model.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3566236      PMCID： PMC174670          DOI： 10.1128/AAC.31.1.129

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Comparison of five regimens for treatment of experimental clindamycin-associated colitis.

Authors:  J G Bartlett; T W Chang; A B Onderdonk
Journal:  J Infect Dis       Date:  1978-07       Impact factor: 5.226

2.  Relapse of pseudomembranous colitis after vancomycin therapy.

Authors:  W L George; N A Volpicelli; D B Stiner; D D Richman; E J Liechty; H Y Mok; R D Rolfe; S M Finegold
Journal:  N Engl J Med       Date:  1979-08-23       Impact factor: 91.245

3.  Colonization resistance of the digestive tract of mice during systemic antibiotic treatment.

Authors:  D van der Waaij; J M Berghuis; J E Lekkerkerk
Journal:  J Hyg (Lond)       Date:  1972-12

4.  Relapse of antibiotic associated colitis: endogenous persistence of Clostridium difficile during vancomycin therapy.

Authors:  B A Walters; R Roberts; R Stafford; E Seneviratne
Journal:  Gut       Date:  1983-03       Impact factor: 23.059

5.  Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis.

Authors:  J G Bartlett; F J Tedesco; S Shull; B Lowe; T Chang
Journal:  Gastroenterology       Date:  1980-03       Impact factor: 22.682

6.  Relapse of antibiotic-associated colitis after vancomycin therapy.

Authors:  I J Wilkinson; G Rich; B Moore; C R Philpot
Journal:  Med J Aust       Date:  1980-04-05       Impact factor: 7.738

7.  Detection of Clostridium difficile toxins A (enterotoxin) and B (cytotoxin) in clinical specimens. Evaluation of a latex agglutination test.

Authors:  L R Peterson; J J Holter; C J Shanholtzer; C R Garrett; D N Gerding
Journal:  Am J Clin Pathol       Date:  1986-08       Impact factor: 2.493

8.  [Comparative effect of a single or continuous administration of "Saccharomyces boulardii" on the establishment of various strains of "candida" in the digestive tract of gnotobiotic mice].

Authors:  R Ducluzeau; M Bensaada
Journal:  Ann Microbiol (Paris)       Date:  1982 Nov-Dec

9.  Cultures for Clostridium difficile in stools containing a cytotoxin neutralized by Clostridium sordellii antitoxin.

Authors:  S H Willey; J G Bartlett
Journal:  J Clin Microbiol       Date:  1979-12       Impact factor: 5.948

10.  Clostridium difficile and cytotoxin in feces of patients with antimicrobial agent-associated pseudomembranous colitis.

Authors:  W L George; R D Rolfe; G K Harding; R Klein; C W Putnam; S M Finegold
Journal:  Infection       Date:  1982       Impact factor: 3.553
View more
  14 in total

1.  Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate.

Authors:  D M Lyerly; E F Bostwick; S B Binion; T D Wilkins
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

2.  Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa.

Authors:  I Castagliuolo; M F Riegler; L Valenick; J T LaMont; C Pothoulakis
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

Review 3.  Clostridium difficile: its disease and toxins.

Authors:  D M Lyerly; H C Krivan; T D Wilkins
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

4.  Treatment of Recurrent Clostridium difficile Diarrhea.

Authors:  Elizabeth S Huebner; Christina M Surawicz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-03

5.  Influence of antibiotics on the recovery and kinetics of Saccharomyces boulardii in rats.

Authors:  A V Boddy; G W Elmer; L V McFarland; R H Levy
Journal:  Pharm Res       Date:  1991-06       Impact factor: 4.200

6.  Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice.

Authors:  A Qamar; S Aboudola; M Warny; P Michetti; C Pothoulakis; J T LaMont; C P Kelly
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 7.  Models for the study of Clostridium difficile infection.

Authors:  Emma L Best; Jane Freeman; Mark H Wilcox
Journal:  Gut Microbes       Date:  2012-03-01

8.  Uptake of yeast (Saccharomyces boulardii) in normal and rotavirus treated intestine.

Authors:  J Cartwright-Shamoon; G R Dickson; J Dodge; K E Carr
Journal:  Gut       Date:  1996-08       Impact factor: 23.059

9.  Studies on the time course of the effects of the probiotic yeast Saccharomyces boulardii on electrolyte transport in pig jejunum.

Authors:  B Schroeder; C Winckler; K Failing; G Breves
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

10.  Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii.

Authors:  M B Kimmey; G W Elmer; C M Surawicz; L V McFarland
Journal:  Dig Dis Sci       Date:  1990-07       Impact factor: 3.199
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.